title: (+)-Borneol attenuates oxaliplatin-induced neuropathic hyperalgesia in mice.
abstract: Common chemotherapeutic agents such as oxaliplatin often cause neuropathic pain during cancer treatment in patients. Such neuropathic pain is difficult to treat and responds poorly to common analgesics, which represents a clinical challenge. (+)-Borneol, a bicyclic monoterpene present in the essential oil of plants, is used for analgesia and anesthesia in traditional Chinese medicine. Although borneol has an antinociceptive effect on acute pain models, little is known about its effect on chemotherapy-induced neuropathic pain and its mechanism. We found that (+)-borneol exerted remarkable antihyperalgesic effects in a mouse model of oxaliplatin-induced neuropathic pain. In addition, (+)-borneol blocked the action of the transient receptor potential ankyrin 1 agonist in mechanical and cold stimulus tests. Repeated treatment with (+)-borneol did not lead to the development of antinociceptive tolerance and did not affect body weight and locomotor activity. (+)-Borneol showed robust analgesic efficacy in mice with neuropathic pain by blocking transient receptor potential ankyrin 1 in the spinal cord and may be a useful analgesic in the management of neuropathic pain.
authors.affiliation: aDepartment of Pharmacy, Division of Clinical Pharmacy, Drum Tower Hospital Affiliated to Medical School of Nanjing University bPharmacy Department, The First Affiliated Hospital cSchool of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
authors.forename: Hai-Hui
authors.initials: HH
authors.lastname: Zhou
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Qi-Gang
authors.initials: QG
authors.lastname: Zhou
authors.forename: Yun
authors.initials: Y
authors.lastname: Fang
authors.forename: Wei-Hong
authors.initials: WH
authors.lastname: Ge
mesh_terms: D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001892:Camphanes / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D006930:Hyperalgesia / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009437:Neuralgia / Q000139:chemically induced / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D000074025:TRPA1 Cation Channel; D050051:Transient Receptor Potential Channels / Q000819:agonists / Q000037:antagonists & inhibitors*
chemical_list: D000700:Analgesics; D000970:Antineoplastic Agents; D001892:Camphanes; D009944:Organoplatinum Compounds; D000074025:TRPA1 Cation Channel; D050051:Transient Receptor Potential Channels; C475685:Trpa1 protein, mouse; D000077150:Oxaliplatin; C022871:isoborneol